Cool... I'll copy and paste your post over here too:
DewDiligence Share Monday, April 04, 2011 2:47:29 PM
Re: DewDiligence post# 113840 Post # of 117559
PFE sells Capsugel business unit for $2.4B in cash:
#msg-61690988
The cash proceeds from this deal will allow PFE to increase share buybacks above the $5B authorization announced in February (#msg-59431699), which is IMO the best use of PFE’s capital. (I.e. PFE’s balance sheet still has plenty of room to add leverage.)
Absent the $750M annual revenue from the Capsugel unit, PFE has adjusted its 2011 and 2012 revenue guidance by a corresponding amount: the new ranges are $65.2-$67.2B in 2011 and $63.0-65.5B in 2012, the first full year after Lipitor goes generic.
PFE’s revenue from emerging markets was only a small portion of the total in 2010 ($2.4B), but it is growing at a very rapid clip (#msg-59590951).
There is not change in non-GAAP EPS guidance on account of the Capsugel deal: the ranges remain $2.16-2.26 in 2011 and $2.25-$2.35 in 2012 (#msg-59431699).
DewDiligence Share Monday, April 04, 2011 2:47:29 PM
Re: DewDiligence post# 113840 Post # of 117559
PFE sells Capsugel business unit for $2.4B in cash:
#msg-61690988
The cash proceeds from this deal will allow PFE to increase share buybacks above the $5B authorization announced in February (#msg-59431699), which is IMO the best use of PFE’s capital. (I.e. PFE’s balance sheet still has plenty of room to add leverage.)
Absent the $750M annual revenue from the Capsugel unit, PFE has adjusted its 2011 and 2012 revenue guidance by a corresponding amount: the new ranges are $65.2-$67.2B in 2011 and $63.0-65.5B in 2012, the first full year after Lipitor goes generic.
PFE’s revenue from emerging markets was only a small portion of the total in 2010 ($2.4B), but it is growing at a very rapid clip (#msg-59590951).
There is not change in non-GAAP EPS guidance on account of the Capsugel deal: the ranges remain $2.16-2.26 in 2011 and $2.25-$2.35 in 2012 (#msg-59431699).
Recent PFE News
- European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors • Business Wire • 05/13/2026 10:45:00 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/12/2026 09:05:04 PM
- Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant) • GlobeNewswire Inc. • 05/12/2026 11:00:00 AM
- The Next Generation of the GLP-1 Revolution Is Already Underway • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- The Next Generation of the GLP-1 Revolution Is Already Underway • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/05/2026 08:42:09 PM
- Pfizer tops Q1 expectations on growth from newer products • IH Market News • 05/05/2026 03:05:10 PM
- Wall Street Set for Rebound as Oil Prices Retreat Sharply: Dow Jones, S&P, Nasdaq, Futures • IH Market News • 05/05/2026 01:19:45 PM
- Wall Street Poised for Gains as Oil Prices Retreat: Dow Jones, S&P, Nasdaq, Futures • UK Market News • 05/05/2026 01:19:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/05/2026 11:03:03 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 11:01:20 AM
- Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance • Business Wire • 05/05/2026 10:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:20:12 PM
- Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma • Business Wire • 04/29/2026 10:45:00 AM
- Pfizer Reaches Three Settlement Agreements for VYNDAMAX • Business Wire • 04/28/2026 02:17:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/27/2026 10:40:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/27/2026 10:39:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/27/2026 10:37:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/27/2026 10:37:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/27/2026 10:37:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/27/2026 10:37:54 PM
- Form 3/A - Initial statement of beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 04/27/2026 10:23:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/27/2026 10:22:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/27/2026 10:22:30 PM

